



Comparative Cytotoxic Assessment of Hydro-Methanolic Extracts Derived from Ripe *Morinda citrifolia* L. Fruit (Fresh, Dried, Pasteurized Juice) and Dried Seeds on Eukaryotic Normal and Carcinogenic Cellular Models [†]

Haththotuwa Gamage Amal Sudaraka Samarasinghe ^{1,2,*} , Dona Chamara Kumari Illeperuma ¹
and Katugampalage Don Prasanna Priyantha Gunathilake ³

¹ Department of Food Science & Technology, Faculty of Agriculture, University of Peradeniya, Kandy 20400, Sri Lanka; dchamaraki@hotmail.com

² Research and Innovation Division, KIU, Battaramulla 10120, Sri Lanka

³ Department of Food Science & Technology, Faculty of Livestock, Fisheries & Nutrition, Wayamba University of Sri Lanka, Makandura 60170, Sri Lanka; kdppgunathilake@yahoo.com

* Correspondence: amalsudaraka@gmail.com; Tel.: +94-704018144

[†] Presented at the 4th International Electronic Conference on Foods, 15–30 October 2023; Available online: <https://foods2023.sciforum.net/>.

Abstract: Noni (*Morinda citrifolia* L.) is utilized for wellness drinks, puree, and nutraceuticals, while its seeds are a source of vegetable oil. However, misconceptions persist due to limited scientific research in Sri Lanka. This study evaluated the cytotoxic effects of hydro-methanolic extracts from fresh and dried noni fruits, pasteurized juice, and seeds on normal (BHK) and cancer (Hep2) cells using the MTT assay. The results indicated dose-dependent toxicity on cancer cells, while normal cells were less affected. Processing methods influenced cytotoxicity, with dried seeds showing the least toxicity. These findings suggest the potential of noni extracts as cytotoxic agents against cancer, influenced by the processing conditions. Further research is needed to identify the specific bioactive compounds and their mechanisms.

Keywords: Noni (*Morinda citrifolia* L.); cytotoxicity; nutraceuticals



Citation: Samarasinghe, H.G.A.S.; Illeperuma, D.C.K.; Gunathilake, K.D.P.P. Comparative Cytotoxic Assessment of Hydro-Methanolic Extracts Derived from Ripe *Morinda citrifolia* L. Fruit (Fresh, Dried, Pasteurized Juice) and Dried Seeds on Eukaryotic Normal and Carcinogenic Cellular Models. *Biol. Life Sci. Forum* **2023**, *26*, 93. <https://doi.org/10.3390/Foods2023-15511>

Academic Editor: Hamada Elwan

Published: 31 October 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Noni (*Morinda citrifolia* L.) fruit, locally known as ‘Ahu’, is a traditional medicinal plant in Sri Lanka. However, it is not widely consumed or processed due to perceived myths [1]. However, due to its remarkable ability to thrive in harsh environments, even under drought conditions, it is commonly referred to as the ‘Starvation fruit,’ consequently, it will potentially contribute to the development of new applications and products with minimal adverse effects [2]. Noni fruit juice has been recognized as a novel food product by the European Union [3]. Meanwhile, approval has been granted to expand the utilization of Polynesian noni fruit puree and fruit juice concentrate as novel food ingredients across a range of food categories [4]. Therefore, several dietary supplements made from noni, such as juice, capsules, powder, concentrates, and tea, are currently available in the market [5]. *M. citrifolia* has been used as a medicine to maintain good health and prevent various diseases like those affecting the skin, brain, gastrointestinal tract (GIT), heart, liver, and cancer. Currently, the only recommended daily oral dose of *M. citrifolia* is 2 g [6]. Noni seeds are also a potential source of functional food [7], and Noni seed oil (NSO) is non-toxic [8] and possesses a unique fatty acid composition, rendering it an attractive option for utilization in the food, pharmaceutical, and cosmetic industries. This offers potential benefits in terms of enhancing nutritional quality [9], structural attributes, aroma, and stability in various formulated food products [10,11].

Publications highlight the health benefits of noni components (fruit, leaf, stem, and seeds), but safety reports are limited. Regular noni juice consumption reportedly does not cause toxic effects, such as acute toxicity, hepatotoxicity, or sub-chronic toxicity [12]. Despite the worldwide use and pharmacological significance of noni fruit and seeds, the effect of this fresh fruit flesh, dried fruit flesh, pasteurized juice, and dried seeds on cancer and also on normal cells has not yet been examined. This in vitro study was undertaken to demonstrate the effect of the extract of *M. citrifolia* on human laryngeal carcinoma (Hep2) cells and baby hamster kidney (BHK) cells. The purpose of the study was to determine whether this compound had a selective cytotoxic effect against cancer cells. An MTT-based cytotoxic assay was carried out using a cancer cell line and a normal cell line.

2. Methodology

Ripened Noni fruits were obtained from trees grown in the Katugathota area of the Kandy district, Sri Lanka. The selected fruits, based on color and shape, were vacuum-packaged in polyethylene bags and stored at -18°C until further analysis.

Methanolic extracts from the fresh fruit flesh, dried fruit flesh, pasteurized juice, and dried seeds were prepared using a modified methodology as described by [13]. Each sample of ground fruit flesh (1.00 g), dried fruit flesh (1.00 g), dried seeds (1.00 g), and pasteurized juice (1.00 mL) was combined with 15 mL of an 80% methanol/water mixture (*v/v*) to create the extracts. These mixtures were allowed to soak overnight, followed by high-speed vortexing for 5 min and centrifugation at $2600\times g$ for 10 min at room temperature using an EBA 20 centrifuge from Hettich, Tuttlingen, Germany. The obtained extracts were then filtered using Whatman No. 42 filter paper from Whatman Paper Ltd., Maidstone, UK. Subsequently, the filtered extracts were evaporated in a rotary evaporator (HAHNAPOR, Model HS-2005 V, HAHNSHIN Scientific, Korea) under vacuum conditions at 40°C . The resulting evaporated extracts were stored at -18°C until analysis, within a period of 1 week.

HepG2 (human hepatoma) cells and baby hamster kidney (BHK) cells were harvested by following the methodology explained in the study conducted by [14] to evaluate cell viability. The cells were harvested by trypsinization and then plated at a density of 5×10^3 cells per well in a 96-well cell culture plate. They were maintained in Dulbecco's Modified Eagle Medium (DMEM) for 24 h at 37°C in an atmosphere of 95% air and 5% CO_2 , with 95% humidity. Cultures were exposed only to medium (1% DMSO, controls) or medium containing different concentrations of methanolic extracts dissolved in 1% DMSO (ranging from 300 $\mu\text{g/mL}$ to 4800 $\mu\text{g/mL}$) and incubated for 24 h. At the end of this incubation period, cells were briefly washed with Phosphate Buffered Saline (PBS).

The method described by [15] was employed to assess cell viability using the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. After pretreating with different concentration series for each of the noni extracts (including fresh fruit, dried fruit, pasteurized juice, and dried seeds) for 24 h, the cells were exposed to 20 mL of PBS for 30 min. Next, 5 mg/mL of MTT was added to each well and incubated for an additional 2 h. The medium was then removed via aspiration. Finally, 150 μL DMSO was added per well, and the absorbance was read at 595 nm and 690 nm using a microplate reader (ELx800 Universal Microplate Reader, BIO-TEK INSTRUMENTS, Winooski, VT, USA). The results were expressed as a percentage of the control values.

3. Results

The cytotoxic assessment of hydro-methanolic extracts derived from ripe *Morinda citrifolia* L. fruit (Fresh, Dried, Pasteurized Juice) and dried seeds on eukaryotic normal and carcinogenic cellular models was conducted using the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. The viability of both normal and cancerous cells, with an initial seeding density of 5×10^3 cells per well in a 96-well cell culture plate, was evaluated after treatment with the respective extracts for 24 h. The results, as presented in Table 1, indicated a general dose–response decrease in cell viability.

Table 1. In vitro Cytotoxicity of Crude Extract of *M. citrifolia* Fruit (Fresh, Dried, Pasteurized Juice) and Dried Seeds on BHK and Hep 2 Cell Lines.

| Concentration (mg/mL) | Percentage of Inhibition (%) | | | | | | | |
|--------------------------|------------------------------|-----------|-------------------|-----------|-------------------|-----------|------------|-----------|
| | Fresh Fruit Flesh | | Dried Fruit Flesh | | Pasteurized Juice | | Dried Seed | |
| | BHK Cell | Hep2 Cell | BHK Cell | Hep2 Cell | BHK Cell | Hep2 Cell | BHK Cell | Hep2 Cell |
| 0.1 | 4 ± 0.12 | 17 ± 0.11 | 2 ± 0.34 | 14 ± 0.45 | 3 ± 0.02 | 10 ± 0.59 | 1 ± 0.09 | 8 ± 0.35 |
| 0.2 | 9 ± 0.18 | 24 ± 0.39 | 5 ± 0.23 | 11 ± 0.61 | 4 ± 0.11 | 10 ± 0.86 | 6 ± 0.08 | 8 ± 0.09 |
| 0.4 | 11 ± 0.62 | 33 ± 0.77 | 8 ± 0.38 | 16 ± 0.72 | 4 ± 0.09 | 12 ± 0.12 | 4 ± 0.39 | 8 ± 0.77 |
| 0.8 | 23 ± 0.34 | 45 ± 0.87 | 24 ± 0.57 | 25 ± 0.18 | 13 ± 0.19 | 15 ± 0.18 | 12 ± 0.14 | 17 ± 0.29 |
| 0.9 | 27 ± 0.57 | 49 ± 0.98 | 21 ± 0.48 | 31 ± 0.27 | 12 ± 0.88 | 28 ± 0.71 | 17 ± 0.21 | 24 ± 0.37 |
| 1 | 42 ± 1.12 | 59 ± 0.48 | 35 ± 0.97 | 40 ± 0.32 | 21 ± 0.68 | 30 ± 0.36 | 16 ± 0.33 | 23 ± 0.10 |
| 2 | 67 ± 0.88 | 64 ± 0.88 | 53 ± 0.66 | 58 ± 1.01 | 49 ± 0.19 | 49 ± 0.91 | 36 ± 1.03 | 43 ± 0.26 |

Note: Values are mean ± SD.

For normal cells, the viability ranged between (4–67)%, (2–53)%, (3–49)%, and (1–36)% when pretreated with methanolic-extracted ripe *Morinda citrifolia* L. fruit (Fresh, Dried, Pasteurized Juice) and Dried Seeds, respectively. The IC₅₀ values for these extracts on normal baby hamster kidney (BHK) cells were IC₅₀(BHK)-0.9759 mg/mL, IC₅₀(BHK)-1.0409 mg/mL, IC₅₀(BHK)-1.1824 mg/mL, and IC₅₀(BHK)-1.6822 mg/mL, respectively.

In the case of carcinoma cells, the viability ranged between (17–64)%, (14–58)%, (10–49)%, and (8–43)% when pretreated with methanolic-extracted ripe *Morinda citrifolia* L. fruit (fresh, dried, and pasteurized juice) and dried seeds, respectively. The IC₅₀ values for these extracts on human laryngeal carcinoma (Hep2) cells were IC₅₀(Hep2)-0.674 mg/mL, IC₅₀(Hep2)-0.9537 mg/mL, IC₅₀(Hep2)-0.9716 mg/mL, and IC₅₀(Hep2)-1.08 mg/mL, respectively.

Furthermore, the effect on normal cells was compared to one cancer cell line (Hep2) to assess selectivity. The results indicated that, unlike normal cells, the extracts from both the fruit (Fresh, Dried, Pasteurized Juice) and Dried Seeds appeared to exhibit dose-dependent toxicity towards cancer cells. Additionally, the inhibition effect on normal cell lines' viability increased as follows: fresh noni fruit flesh, dried noni fruit flesh, pasteurized noni fruit juice, and dried noni seed. This pattern was also observed in the inhibition effect on cancer cell lines' viability. Notably, the reduction in the proliferation rate of Hep2 cells was significantly higher for each crude extract compared to the reduction observed in eukaryotic normal cells (baby hamster kidney (BHK) cells). This observation suggests that the cytotoxic effects may have implications for human eukaryotic cells as well.

4. Conclusions

The results of this study underscore the remarkable potential of fresh *Morinda citrifolia* L. fruit, dried fruit, pasteurized fruit juice, and dried *Morinda citrifolia* seeds as powerful anti-proliferative food supplements. The observed dose-dependent inhibitory effect on cancer cell growth, along with the selectivity exhibited towards malignant cells compared to normal cells, highlights the promising role of these extracts in potential cancer therapies. The heightened impact on normal cell lines, coupled with the significant reduction in cancer cell viability, suggests a potential avenue for natural anti-cancer strategies. Further research should focus on unraveling the specific mechanisms behind this selectivity alongside comprehensive investigations into the safety and bioavailability of these compounds, ultimately aiming to integrate these findings into the development of effective and safe anti-proliferative food supplements for potential oncological interventions.

Author Contributions: Conceptualization, D.C.K.I. and H.G.A.S.S.; methodology, K.D.P.P.G. software, K.D.P.P.G.; validation, K.D.P.P.G. and H.G.A.S.S.; formal analysis, H.G.A.S.S.; investigation, H.G.A.S.S.; resources, K.D.P.P.G.; data curation, K.D.P.P.G.; writing—original draft preparation, H.G.A.S.S.; writing—review and editing, K.D.P.P.G.; visualization, H.G.A.S.S.; supervision, D.C.K.I. and K.D.P.P.G.; project administration, K.D.P.P.G.; funding acquisition, K.D.P.P.G. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the World Bank AHEAD project under the research grant AHEAD/RA3/DOR/WUSL/FST.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Summary data are available upon request.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Samarasinghe, H.G.A.S.; Illeperuma, D.C.K.; Gunathilake, K.D.P.P. Evaluation of Bioactive Compounds, Antioxidant, Anti-Diabetic, and Anti-Inflammatory Properties of Pasteurized Juice from the Noni Fruits (*Morinda citrifolia* L.) Growing in Sri Lanka. In Proceedings of the International Conference on Applied Sciences, Faculty of Applied Sciences, Sabaragamuwa University, Belihuloya, Sri Lanka, 30–31 May 2023; Volume 52.
2. Patil, P.; Madkaikar, H.; Shah, N. *Morinda citrifolia* L. (Noni)—Its Ethnobotanical Knowledge, Phytochemical Studies, Pharmacological Aspects, And Future Prospects. *Int. J. Nov. Res. Dev. (IJNRD)* **2022**, *7*, 331–352. Available online: www.ijnrd.org (accessed on 12 April 2023).
3. EU SCF (Scientific Committee on Food). Opinion of the Scientific Committee on Food on Tahitian Noni ® Juice. SCF/CS/NF/DOS/18 ADD 2 Final. December 2002, pp. 1–68. Available online: http://europa.eu.int/comm/food/fs/sc/scf/out151_en.pdf. (accessed on 8 April 2023).
4. European Commission. Commission Decision of 21 April 2010 authorizing the placing on the market of puree and concentrate of the fruits of *Morinda citrifolia* as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council. *Off. J. Eur. Union* **2010**, *102*, 49–51.
5. Kulathunga, S.; Arawwawala, L.D. *Morinda citrifolia* Linn Grown in Sri Lanka: Shelf Life of Fruit Juice. *Am. J. Ethnomed.* **2017**, *4*, 18. [CrossRef]
6. Abou Assi, R.; Darwis, Y.; Abdulbaqi, I.M.; Khan, A.A.; Vuanghao, L.; Laghari, M.H. *Morinda citrifolia* (Noni): A comprehensive review on its industrial uses, pharmacological activities, and clinical trials. *Arab. J. Chem.* **2017**, *10*, 691–707. [CrossRef]
7. West, B.J.; Jarakae Jensen, C.; Westendorf, J. A new vegetable oil from noni (*Morinda citrifolia*) seeds. *Int. J. Food Sci. Technol.* **2008**, *43*, 1988–1992. [CrossRef]
8. West, B.J.; Jarakae Jensen, C.; PaIu, A.K.; Deng, S. Toxicity and antioxidant tests of *Morinda citrifolia* (noni) seed extract. *Adv. J. Food Sci. Technol.* **2011**, *3*, 303–307.
9. Pazos, D.C.; Jiménez, F.E.; Garduño, L.; López, V.E.; Cruz, M.C. Hypolipidemic effect of seed oil of Noni (*Morinda citrifolia*). *Nat. Prod. Commun.* **2011**, *6*, 1005–1008. [CrossRef] [PubMed]
10. Fontes, R.F.; Andrade, J.K.S.; Rajan, M.; Narain, N. Chemical characterization of different parts of noni (*Morinda citrifolia*) fruit and its freeze-dried pulp powder with emphasis on its bioactive compounds and antioxidant activities. *Food Sci. Technol.* **2023**, *43*, 1–8. [CrossRef]
11. Jahurul, M.H.A.; Patricia, M.; Shihabul, A.; Norazlina, M.R.; George, M.R.R.; Noorakmar, W.; Lee, J.S.; Jumardi, R.; Jinap, S.; Zaidul, I.S.M. Food Bioscience A review on functional and nutritional properties of noni fruit seed (*Morinda citrifolia* L.) and its oil. *Food Biosci.* **2021**, *41*, 101000. [CrossRef]
12. Shin, S.; Kim, J.S.; Park, M.K.; Bang, O.S. Genotoxicity Comparison between *Morinda citrifolia* Fruit and Seed Substances. *Foods* **2022**, *11*, 1773. [CrossRef] [PubMed]
13. Samarasinghe, H.G.A.S.; Illeperuma, D.C.K.; Gunathilake, K.D.P.P. Evaluation of antioxidant, anti-inflammatory and anti-diabetic properties of noni fruit (*Morinda citrifolia* L.) and its simulated gastrointestinal digesta fractions. *J. Food Bioprocess Eng.* **2023**, *6*, 59–68. [CrossRef]

14. Samarakoon, S.R.; Thabrew, I.; Galhena, P.B.; De Silva, D.; Tennekoon, K.H. A Comparison of the Cytotoxic Potential of Standardized Aqueous and Ethanolic Extracts of a Polyherbal Mixture Comprised of *Nigella sativa* (seeds), *Hemidesmus indicus* (roots), and *Smilax glabra* (rhizome). *Pharmacogn. Res.* **2010**, *2*, 335–342. [[CrossRef](#)] [[PubMed](#)]
15. Ruhomally, Z.; Somanah, J.; Bahorun, T.; Neergheen-Bhujun, V.S. *Morinda citrifolia* L. fruit extracts modulate H₂O₂-induced oxidative stress in human liposarcoma SW872 cells. *J. Tradit. Complement. Med.* **2016**, *6*, 299–304. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.